You are here

Prices & Quotes - UK Markets - Circassia Group (CIR)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Share Price:
Down 41.00p
Change Today:
-1.65p
Market Cap:
171.57m
Sector:
Health Care Equipment & Services

Circassia shares rise as it flags 'significant' revenue growth

By Josh White

Date: Thursday 09 Jan 2020

LONDON (ShareCast) - (Sharecast News) - Respiratory disease-focussed pharmaceutical company Circassia Pharmaceuticals updated the market on its trading for the year ended 31 December on Thursday, announcing that it expected revenues for the year to fall in the mid-range of its previously issued guidance of between 60m and 65m.
The AIM-traded firm said that still represented "significant growth" over the previous year's figure of 48.3m.

It said it was expecting to report growth in both 'NIOX' and 'Tudorza' sales, and a modest contribution from 'Duaklir', which was launched at the end of October.

Additionally, cash, cash equivalents and short-term deposits were about 27m at year-end, down from 40.7m year-on-year but up from 21m at the end of June.

That was higher than anticipated, the board explained, due in part to the timing of certain payments, including for Tudorza and Duaklir inventory, and third-party rebates.

Without the beneficial impact of the timing of those payments, the company said it would have achieved a "significant improvement" in net cash flow in the second half of 2019 compared with the first half, with a "modest" net cash outflow during the second half of the year.

Circassia also announced that its chief financial officer, Julien Cotta, was stepping down on Thursday following eight years in the role.

He would be succeeded by Michael Roller, who was joining the company and board immediately as an executive director and CFO.

The board described Roller as a "highly experienced" finance director and life sciences company director, having previously been group finance director of Bioquell and Corin Group.

He completed his training at KPMG and is a Chartered Accountant and a member of the ICAEW.

Roller graduated from Merton College, Oxford with a BA in History.

"I would like to warmly welcome Michael to Circassia as our new CFO, and to thank Julien for his significant contribution to the company over many years," said executive chairman Ian Johnson.

"Having worked with Michael previously at Bioquell, I look forward to renewing our partnership, as we work to build shareholder value and a profitable cash generative business."

Michael Roller said he was "delighted" to join Circassia.

"I look forward to working with Ian and the whole team at this important time in the company's development as we focus on achieving self-sustainability."

At 1130 GMT, shares in Circassia Pharmaceuticals were up 5.05% at 21.43p.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

CIR Market Data

Currency UK Pounds
Price 41.00p
Change Today -1.65p
52 Week High 46.05p
52 Week Low 23.90p
Volume 246,523
Shares Issued 418.46m
Market Cap 171.57m

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. full market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. half sector star
  3. empty sector
  4. empty sector
  5. empty sector
Price Trend
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. full market star
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. full sector star
Income
Not Available
Growth
market
  1. full market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. half sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
Price Chg 6m
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. half market star
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. full sector star
P/E
Not Available
PEG
market
  1. full market star
  2. full market star
  3. half market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. empty sector
  5. empty sector
Dividend Yield
Not Available
EPS Growth
Not Available
Operating Margin
market
  1. full market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. half sector star
  3. empty sector
  4. empty sector
  5. empty sector

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 2
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

CIR Dividends

No dividends found

Trades for 21-Jan-2022

Time Volume / Share Price
15:55 2,444 @ 40.91p
15:30 25,000 @ 41.10p
15:14 12,077 @ 41.50p
15:08 50,000 @ 41.60p
15:06 14,928 @ 41.55p

CIR Key Personnel